Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 23, 2025Future OncologyOpen Access

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US

View Full Paper
Ask AI
Bookmark
Share

Authors

EMErin MulveyJSJason ShafrinKTKyi‐Sin Than

Discussion

Loading...

Member takes

Overview

Patients express preferences for bispecific antibodies, highlighting the importance of treatment attributes in managing relapse/refractory diffuse large B-cell lymphoma.

Key Points

  • Subcutaneous and intravenous bispecific antibodies are critical options for treatment.
  • Patient preferences emphasize the significance of treatment duration and administration route.
  • Assessment of preferences aids in patient-centered decision-making for managing DLBCL.
  • Understanding these preferences may improve therapeutic strategies and patient satisfaction.

Cite This Study

Mulvey et al. (2025) studied this question.

synapsesocial.com/papers/68fa1210f9f8b44535bfcf34https://doi.org/10.1080/14796694.2025.2572784
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A056: Bispecific T-cell engagers and antibody-drug conjugtes for the treatment of lymphomas2026
  2. 2Patient preferences regarding bispecific antibody (BsAb) treatment schedules and clinical profiles in second-line or later (2L+) diffuse large B-cell lymphoma (DLBCL).2026
  3. 3Effectiveness and safety of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A systematic review and meta-analysis2025
  4. 4Real-world outcomes of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma: A TriNetX retrospective study.2026
  5. 5Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing2026